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Background: Despite management of conventional coronary risk factors, especially plasma low LDL-C, there is a residual risk for development of 
ACS. Recent data have suggested that specific CYPs, such as CYP2C9 and 2C19, localized in vascular smooth muscle and endothelium contribute to 
the regulation of vascular tone or to the progression of atherosclerosis. The aim of this study was to clarify whether CYP2C19 polymorphism would be 
associated with the development of ACS independently of the other risk factors.
Methods:  This study enrolled 161 patients undergoing coronary stent implantation for admission due to ACS (n=59, male 37, 69 yrs), and stable 
angina (n=102, male 69, 69yrs). We analyzed the incidence and predictive value of CYP2C19 *2, or *3 polymorphism according to plasma LDL-C 
levels on admission (<100 vs >100 mg/dl).
Results:  There were no significant differences in patients’ characteristics between low and high LDL-C groups of both ACS and stable angina (SA). 
In ACS with low LDL-C (<100 mg/dl), the distribution of CYP2C19 genotype was 23, 58, and 19 % in the wild-type homozygotes (CYP2C19*1/*1), 
in the *2, or *3 heterozygotes carrying one loss-of-function allele (*1/*2, *1/*3), and in the *2, or *3 homozygotes carrying two loss-of-function 
alleles (*2/*2, *2/*3, *3/*3), respectively. In ACS with high LDL-C (>100mg/dl), the ratio of CYP2C19 genotype was 57, 24, and 19 % in the 
wild-type homozygotes, in the *2 or *3 heterozygotes, and in the *2, or *3 homozygotes, respectively. There was no significant difference in the 
distribution of CYP2C19 polymorphism between low and high LDL-C groups of SA. Moreover, during a 1-year follow-up period, the reccurrence of 
cardiovascular events was more increased in the *2 or *3 hetero- and homozygotes than in the wild-type homozygotes (*1/*1).
Conclusions:  These data suggest that CYP2C19 *2 or *3 loss-of-function allele is associated with a higher incidence and a harmful prognosis of 
ACS in subjects with low LDL-C on admission. Beyond traditional coronary risk factors, CYP2C19 *2, *3 polymorphism seems to have an important 
role in development of ACS.
